Avalglucosidase Alfa (Nexviazyme)

Key Messages

• CADTH recommends that Nexviazyme be reimbursed by public drug plans for the long-term treatment of patients with late-onset Pompe disease (LOPD) if certain conditions are met.
• Nexviazyme should only be covered to treat patients who have a confirmed diagnosis of LOPD, are able to walk, and have never received Myozyme before or were unable to tolerate Myozyme during the first year of treatment. Nexviazyme should not be covered to treat patients who have known Pompe-specific enlargement of the heart muscle, have severe disease, or are unable to perform repeated forced vital capacity (FVC percent predicted) measurements between 30% and 85%.
• Nexviazyme should only be reimbursed if prescribed by a clinician experienced in treating lysosomal storage diseases or other types of neuromuscular diseases and the price is less costly than Myozyme for the treatment of patients with LOPD.